Table 1 Baseline characteristics
From: Outcome of protease inhibitor substitution with nevirapine in HIV-1 infected children
PATIENT | TRANSMISSION | GENDER | Age(years+months) | CATEGORY(CDC) | TANNER * | LIPODYSTROPHY |
|---|---|---|---|---|---|---|
1 | UNKNOWN | GIRL | 13 Y 7 M | A1 | III to V | no |
2 | VERTICAL | BOY | 9 Y 10 M | A3 | I-I | no |
3 | VERTICAL | BOY | 8 Y 3 M | A1 | I-I | no |
4 | VERTICAL | GIRL | 9 Y 2 M | C3 | I-I | no |
5 | VERTICAL | BOY | 10 Y | C3 | I-I | no |
6 | VERTICAL | BOY | 14 Y 7 M | B2 | II-III | lipoatrohy |
7 | VERTICAL | BOY | 8 Y 2 M | B2 | II-III | lipohypertrophy |
MEDIAN | 133(99,177) |